

Medical Research Agency, Poland

Real-world evidence for cardio-toxicology

The Medical Research Agency (MRA)

Through research to health

A governmental entity responsible for the support and conducting research in the medical and health sciences.

The Agency's core task – to ensure proportional funding for medical sciences and health sciences in:

Research and development

Clinical research on medicinal products and medical devices

Epidemiological studies

Studies on management

Development and optimisation of health care system



Funded projects

220 projects

34

Oncology

47

Cardiology

29

Anti-COVID

12

Hematology

16

The Clinical Trials **Development Centre**

11

Pediatrics

Endocrinology

8

Psychiatry

Neurology

Gynecology

5

Respiratory system

5

Urology and nephrology

33

Others

>55k patients

will participate in MRA-funded clinical trials





Non-commercial clinical trials funded by MRA in oncological cardiotoxicology

Silesian Centre for Heart Diseases, Zabrze	4th Military Clinical Hospital, Wrocław	National Institute of Oncology, Warszawa
Sacubitril/valsartan cardioprotection in anthracyclin-treated and anti-HER-2-treated breast cancer patients	Dapagliflozin cardioprotection in anthracyclin- treated breast cancer patients	Empagliflozin cardioprotection in anthracyclin-treated cancer
480 patients	188 patients	220 patients
-	PROTECTAA TRIAL	EPACT TRIAL
PhD, MD Mateusz Tajstra	Prof. PhD MD, Waldemar Banasiak	PhD, MD Anna Borowiec
Study in registration	Study in registration	Registered, recruting



Polish Clinical Trials Network

Establishment of Polish Clinical Trials Network (PCTN)

 systematic implementation of quality and process standards within Polish clinical sites, development of infrastructure, personnel training.





23 Clinical Trial Support Centres

Including 9 sites for early phase clinical trials, and 8 oncological centres



Digital Medicine Centres Network


Call for proposals

Call for entities or consortia thereof having at least one Clinical Trials Support Center To provide digital solutions to support real-time data analysis, clinical trials, and inpatient care, as well as ensure retrospective analysis

Objective –
establishment of the
Digital Medicine
Centres Network
supervised by the
MRA


18 centres funded in September 2023

Allocation: 500 MM PLN






RDMC Pipeline Concept





RDMC Data Sources





RDMC Standard

Goals and Tasks for RDMS

Sources, types, minimum quality and stadnard of data

Required functionalities and obligatory modules of RDMC IT system


Infrastructural requirements— administration, technical capacity, biobank

HR and training requirements – skills- and competencies-driven approach

Regulations concerning safe data processing and system functioning continuity

Regulations concerning planned data sharing within RDMC Network

Expected results and benefits





Translational Medicine Development Plan for 2024-2036

Strategy goal: agile adaptation of scientific discoveries to the clinical practice – bench-to-bedside approach

